Format

Send to

Choose Destination
Fertil Steril. 2015 Nov;104(5):1218-26. doi: 10.1016/j.fertnstert.2015.07.1135. Epub 2015 Aug 10.

Cancer in women after assisted reproductive technology.

Author information

1
Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, Michigan. Electronic address: lukeb@msu.edu.
2
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
3
Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
4
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
5
Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, Michigan.
6
Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, Texas.
7
Illinois State Cancer Registry, Illinois Department of Public Health, Springfield, Illinois.
8
Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan.
9
Department of Obstetrics and Gynecology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
10
Seattle Reproductive Medicine, Seattle, Washington.
11
Bureau of Cancer Epidemiology, New York State Cancer Registry, New York State Department of Health, Albany, New York.

Abstract

OBJECTIVE:

To evaluate the risk of cancer after assisted reproductive technology (ART) therapy.

DESIGN:

Longitudinal cohort study.

SETTING:

Not applicable.

PATIENT(S):

New York, Texas, and Illinois residents between 2004 and 2009, treated with ART, comprising cycles of 113,226 women, including 53,859 women without prior ART treatment, who were linked to their respective state cancer registries and whose cycles were reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System (SART CORS).

INTERVENTION(S):

None.

MAIN OUTCOME MEASURE(S):

Diagnosis of cancer, as reported to the state cancer registry; standardized incidence ratios (SIR) and their 95% confidence intervals, comparing the observed to expected cancer cases based on age-specific cancer rates in the general population of each state.

RESULT(S):

Among the cohort of women without prior ART therapy, hazard ratios (HR) and 95% confidence intervals (CI) were calculated for treatment parameters and reproductive history factors. The mean follow-up period was 4.87 years; among women without prior ART, 450 women developed 460 cancers. Women treated with ART had a statistically significantly lower risk for all cancers (for all women: SIR 0.78; CI, 0.73-0.83; women without prior ART: SIR 0.75; CI, 0.68-0.82), breast cancer, and all female genital cancers; a non-statistically-significant lower risk for endocrine and uterine cancer; and a non-statistically-significant higher risk for melanoma and ovarian cancer. Among women without prior ART, we found no statistically significant increased HR by parity, number of cycles, cumulative follicle-stimulating hormone dosage, or cycle outcome.

CONCLUSION(S):

Women initiating ART treatment have no greater risk for developing cancer after nearly 5 years of follow-up compared with the general population and with other women treated with ART.

KEYWORDS:

Assisted reproductive technology; cancer risk; fertility; pregnancy outcome

PMID:
26271227
PMCID:
PMC4630138
DOI:
10.1016/j.fertnstert.2015.07.1135
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center